Regulation of clinical chemoresistance by bcl-2 and bax oncoproteins in B-cell chronic lymphocytic leukaemia

British Journal of Haematology

Volumn 95, Issue 3, 1996, Pages 513-517

  Pepper, Chris ^a   Bentley, Paul ^a   Hoy, Terry ^b  

^a LLANDOUGH HOSPITAL   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

B CLL; bax; bcl 2; Chemoresponsiveness

Indexed keywords

ONCOPROTEIN; PROTEIN BAX; PROTEIN BCL 2;

ARTICLE; B CELL LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESISTANCE; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 0029858942     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1996.d01-1927.x     Document Type: Article

References (17)

1. Aiello, A., Delia, D., Borrello, M.G., Biassoni, D., Giardini, R., Fontanella, E., Pezzella, F., Pulford, K., Pierotti, M. & Porta, G.D. (1992) Flow cytometric detection of the mitochondrial bcl-2 protein in normal and neoplastic human lymphoid cells. Cytometry, 13, 502-509.
2. Binet, J.L., Auquier, A., Dighiero, G., Chastang, C., Piguet, H., Goasguen, J., Vaugier, G., Potron, G., Colona, P., Oberling, F., Thomas, M., Tchernia, G., Jacquillat, C. & Boivin, P. (1981) A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer, 48, 198-206.
3. Cheson, B.D., Bennett, J.M., Rai, K.R., Grever, M.R., Kay, N.E., Schiffer, C.A., Oken, M.M., Keating, M.J., Boldt, D.H., Kempin, S.J. & Foon, K.A. (1988) Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored Working Group. American Journal of Hematology, 29, 152-163.
4. Dameshek, W. (1967) Chronic lymphocytic leukemia: an accumulative disease of immunologically incompetent lymphocytes. Blood, 29, 566-584.
5. Hanada, M., Aime-Sempe, C., Sato, T. & Reed, J.C. (1995) Structure-function analysis of bcl-2 protein: identification of conserved domains important for homodimerisation with bcl-2 and heterodimerisation with bax. Journal of Biological Chemistry, 270, 11962-11969.
6. Hanada, M., Delia, D., Aiello, A., Stadtmauer, E. & Reed, J.C. (1993) bcl-2 gene hypomethylation and high level expression in B-cell chronic lymphocytic leukemia. Blood, 82, 1820-1828.
7. Hockenbery, D., Nunez, G., Milliman, C., Schreiber, R.D. & Korsmeyer, S.J. (1990) bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature, 348, 334-336.
8. Jacobson, M.D., Burne, J.F., King, M.P., Miyashita, T., Reed, J.C. & Raff, M.C. (1993) bcl-2 blocks apoptosis in cells lacking mitochondrial DNA. Nature, 361, 365-368.
9. Kastan, M.B., Stone, K.D. & Civin, C.I. (1989) Nuclear oncoprotein expression as a function of lineage, differentiation stage, and proliferative activity status of normal hematopoietic cells. Blood, 74, 1517-1524.
10. Korsmeyer, S.J. (1992) bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood, 80, 879-886.
11. Korsmeyer, S.J., Shutter, J.R., Veis, D.J. Merry, D.E. & Oltvai, Z.N. (1993) bcl-2/bax: a rheostat that regulates an anti-oxidant pathway and cell death. Seminars in Cancer Biology, 4, 327-332.
12. Miyashita, T., Krajewski, S., Krajewska, M., Wang, H.G., Lin, H.K., Liebermann, D.A., Hoffman, B. & Reed, J.C. (1994) Tumour suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene, 9, 1799-1805.
13. Oltvai, Z.N., Milliman, C.L. & Korsmeyer, S.J. (1993) bcl-2 heterodimerizes in vitro with a conserved homolog, bax, that accelerates programmed cell death. Cell, 74, 609-619.
14. Reed, J.C. (1995a) bcl-2 family proteins: regulators of chemoresistance in cancer. Toxicology Letters, 82/83, 155-158.
15. Reed, J.C. (1995b) bcl-2: prevention of apoptosis as a mechanism of drug resistance. Hematology/Oncology Clinics of North America, 9, 451-473.
16. Thomas, A., El Rouby, S., Reed, J.C., Krajewski, S., Silber, R., Potmesil, M. & Newcomb, E.W. (1996) Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene, 12, 1055-1062.
17. Yin, X.M., Oltvai, Z.N. & Korsmeyer, S.J. (1994) BH1 and BH2 domains of bcl-2 are required for inhibition of apoptosis and heterodimerisation with bax. Nature, 369, 321-333.